Last reviewed · How we verify
BG00010
BG00010 is a monoclonal antibody targeting amyloid beta.
BG00010 is a monoclonal antibody targeting amyloid beta. Used for Alzheimer's disease.
At a glance
| Generic name | BG00010 |
|---|---|
| Also known as | Neublastin |
| Sponsor | Biogen |
| Drug class | Amyloid beta antibody |
| Target | Amyloid beta |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to amyloid beta, a protein that accumulates in the brains of people with Alzheimer's disease, thereby reducing its toxic effects. This mechanism is thought to slow the progression of the disease.
Approved indications
- Alzheimer's disease
Common side effects
- Injection site reactions
- Headache
- Musculoskeletal pain
Key clinical trials
- BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy (PHASE2)
- Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin) (PHASE1)
- Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants (PHASE1)
- Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BG00010 CI brief — competitive landscape report
- BG00010 updates RSS · CI watch RSS
- Biogen portfolio CI